IDH1 and neoplasm: Patients in both the training and validation cohorts were divided into subgroups according to clinical features, including the age, sex, IDH status, 1p/19q con-deletion status, and WHO classification of the TCGA (Figure 5A) and the CGGA (Figure 5B) patients, as well as the primary/recurrent tumor types of the CGGA patients (Figure 5B).